Ariad Pharmaceuticals Inc. said Monday it filed for U.S. marketing approval of leukemia drug ponatinib.

Ariad said it asked the Food and Drug Administration to approve ponatinib as a treatment for chronic myeloid leukemia and for Philadelphia-chromosome positive acute lymphoblastic leukemia, a more aggressive type of leukemia. The company said it will submit additional data on matters including the manufacturing and chemistry of ponatinib during the third quarter. Ariad also plans to file for marketing approval in Europe during the current quarter.

The company said it expects the FDA to approve the drug during the first quarter of 2013, and it plans to launch ponatinib during that quarter as well.

Shares of Ariad rose 18 cents to $19.09 Monday and reached an all-time high of $19.17.